BioNTech SE — Regulatory Filings 2019

Dec 17, 2019

6-K 1 bntx-6k_20191217.htm 6-K PRESS RELEASE EIB LOAN HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd" bntx-6k_20191217.htm NG Converter v5.0.19273.161

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

FOR THE MONTH OF DECEMBER 2019

COMMISSION FILE NUMBER 001-39081

BioNTech SE (Translation of registrant’s name into English)

An der Goldgrube 12

D-55131 Mainz

Germany

+49 6131-9084-0 (Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20‑F or Form 40‑F: Form 20‑F ☒ Form 40‑F ☐

Indicate by check mark if the registrant is submitting the Form 6‑K in paper as permitted by Regulation S‑T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6‑K in paper as permitted by Regulation S‑T Rule 101(b)(7) : ☐

DOCUMENTS INCLUDED AS PART OF THIS FORM 6-K

On December 17, 2019, BioNTech SE (the “Company”) issued a press release, attached hereto as Exhibit 99.1, announcing that the Company and the European Investment Bank has entered into a contract, which provides €50 million of financing to the Company.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

BioNTech SE

By:
Name: Dr. Sierk Poetting
Title: Chief Financial Officer

Date: December 17, 2019

EXHIBIT INDEX

Exhibit	Description of Exhibit
99.1	Press Release dated December 17, 2019 - BioNTech SE Provides Update on European Investment Bank funding of €50 million as part of the Investment Plan for Europe.